What is claimed is:
1. A method for modeling a stimulation treatment for a reservoir, comprising the steps of:
obtaining a set of quantified reservoir parameters including the reservoir minerals;
designing a first treatment fluid comprising a mixture of chemical species;
obtaining a first set of chemical reactions that can occur between the minerals and the component of the treatment fluid; said reactions defined by their equilibrium and their kinetic properties;
selecting a subset of said first set of chemical reactions to create a reaction model of said minerals with said treatment fluid and predict damages consecutive of the treatment; and
iteratively adjusting the stimulation treatment to optimize results.
2. The method of claim 1, wherein the quantified reservoir parameters include an estimate of the quantity and depth of damage to reservoir.
3. The method of claim 2, wherein the damage data includes scales.
4. The method of claim 2, wherein the damage data includes fine migration.
5. The method of claim 2, wherein the damage data are estimated from nodal analysis and mud and resistivity log data.
6. The method of claim 1, wherein the iterative step includes performing a sensitivity analysis to optimize the variables for selecting an optimum treatment design.
7. The method of claim 1, wherein the set of quantified reservoir parameters includes permeability.
8. The method of claim 7, further including a step of modeling a core test for at least one injection rate of fluid treatment, assuming a linear flow.
9. The method of claim 8, wherein the treatment includes pumping a sequence of successive fluid treatments at specific rates.
10. The method of claim 9, wherein the step of iteratively adjusting the stimulation treatment includes the step of adjusting the pumping sequence.
11. A method for modeling a stimulation treatment for a reservoir, comprising the steps of:
obtaining a set of quantified reservoir parameters including the reservoir minerals, permeability and the quantity and depth of damage to the reservoir;
modeling a reservoir core having a length and a diameter;
designing a first treatment fluid comprising a mixture of chemical species;
obtaining a first set of chemical reactions that can occur between the minerals and the component of the treatment fluid; said reactions defined by their equilibrium and their kinetic properties;
selecting an injection rate of the treatment fluid;
selecting a subset of said first set of chemical reactions to create a reaction model of sail core with said treatment fluid and predict damages consecutive of the treatment; and
iteratively adjusting the stimulation treatment to optimize results.
12. The method of claim 11, wherein the reaction model of said core assumes a linear flow of the treatment fluid along the core.
13. The method of claim 11, wherein the reaction model of said core includes effluent analysis and permeability evolution.
14. The method of claim 11, wherein said set of quantified reservoir parameters includes porosity and said remain model includes porosity evolution.
15. A method for modeling a stimulation treatment for a reservoir, comprising the steps of:
obtaining a set of quantified reservoir parameters including the reservoir minerals, permeability and the quantity and depth of damage to the reservoir;
designing a first treatment fluid comprising a mixture of chemical species;
obtaining a first set of chemical reactions that can occur between the minerals and the component of the treatment fluid; said reactions defined by their equilibrium and their kinetic properties;
selecting an injection rate of the treatment fluid;
selecting a subset of said first set of chemical reactions to create a reaction model of said reservoir with said treatment fluid and predict damages consecutive of the treatment; and
iteratively adjusting the stimulation treatment to optimize results.
16. The method of claim 14, wherein the damage data are estimated from nodal analysis and mud and resistivity log data.
17. The method of claim 14, wherein the iterative step includes performing a sensitivity analysis to optimize the variables for selecting an optimum treatment design.
18. The method of claim 14, wherein the reaction model assumes a radial flow of the treatment fluid.
19. The method of claim 14, wherein the reaction model of said reservoir includes effluent analysis and permeability evolution.
20. The method of claim 14, wherein the models comprises both aqueous species and minerals, and wherein the assumption Gi, Pr, Tr0Gi, P, Tr0 is used, and wherein the chemical species is available in equilibrium constant form, i0 (T, P) for the specie can be calculated from the following thermodynamic identity:
14
ln
(
K
)
=
–
i
i
o
RT
21. The method of claim 19, wherein once the i0 (T, P) for the aqueous species i is computed at stimulation temperature and pressure, the chemical potential of the aqueous specie in solution is then computed internally in the simulator from the following equation:
i(T, P, {right arrow over (m)})i0(T, P)RTlni(T, P, {right arrow over (m)})m
22. A method for performing a stimulation treatment for a reservoir, comprising the steps of:
obtaining a set of quantified reservoir parameters including the reservoir minerals, permeability and the quantity and depth of damage to the reservoir;
designing a first treatment fluid comprising a mixture of chemical species;
obtaining a first set of chemical reactions that can occur between the minerals and the component of the treatment fluid; said reactions defined by their equilibrium and their kinetic properties and therefore creating a mathematical model of the treatment;
selecting an injection rate of the first treatment fluid;
selecting a subset of said first set of chemical reactions to create a reaction model of said reservoir with said treatment fluid and predict damages consecutive of the treatment;
pumping said first treatment fluid at a first injection rate while measuring the bottomhole pressure;
computing real-time damages to the reservoir from the measured bottomhole pressure and injection rate;
simultaneously computing the damages based on the mathematical model; and
adjusting the stimulation treatment to optimize results.
23. A method for designing a stimulation treatment fluid for a reservoir, comprising the steps of:
obtaining a set of quantified reservoir parameters including the reservoir minerals;
designing a first treatment fluid comprising a mixture of chemical species;
obtaining a first set of chemical reactions that can occur between the minerals and the component of the treatment fluid; said reactions defined by their equilibrium ad their kinetic properties and therefore creating a mathematical model of the treatment;
selecting a subset of said first set of chemical reactions to create a reaction model of said reservoir minerals with said treatment fluid and predict damages consecutive of the treatment;
iteratively adjusting the stimulation treatment to optimize results; and
performing laboratory experiments on the optimized stimulation treatments thereby reducing the number of experiments required for designing a new treatment.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An immunogen of the formula:
wherein Z1 is hydrogen; and Z4 is selected from the group consisting of a crosslinker coupled to an antigenicity-conferring carrier material and
wherein Z2 is a crosslinker coupled to an antigenicity-conferring carrier material at an ortho, a meta or a para position.
2. The immunogen of claim 1, wherein the crosslinker of Z2 is at the para position.
3. The immunogen of claim 1, wherein the crosslinker terminates, at its free end, with \u2014CO\u2014R, in which R is selected from the group consisting of hydroxyl and a short chain (C1-5) alkyl moiety.
4. The immunogen of claim 3, wherein R is a short chain (C1-2) alkyl moiety.
5. The immunogen of claim 1, wherein the crosslinker comprises:
\u2014(NH)a\u2014(CO)b\u2014Xc\u2014(CH2)d\u2014Se\u2014CO\u2014R
wherein, independently, a is 0 or 1; b is 0 or 1; X is oxygen or sulfur; c is 0 or 1; d is selected from the integers 1\u20135; e is 0 or 1 and R is selected from the group consisting of a short chain alkyl (C1-5) moiety and a hydroxyl moiety or a, b, c and d are 0, e is 1 and R is methyl.
6. The immunogen of claim 1, wherein the crosslinker comprises:
\u2014(NH)a\u2014(CO)b\u2014Xc\u2014(CH2)d\u2014Se\u2014CO\u2014R
wherein, independently, a is 0 or 1; b is 0 or 1; X is oxygen or sulfur; c is 0 or 1; d is selected from the integers 0\u20135; e is 0 or 1 and R is selected from the group consisting of a short chain alkyl (C1-5) moiety and a hydroxyl moiety.
7. The immunogen of claim 5 or 6, wherein R is a short chain alkyl (C1-2) moiety.
8. The immunogen of claim 5 or 6, wherein a is 1; b is 1; c is 0; and d is 2.
9. The immunogen of claim 8, wherein e is 1; and R is methyl.
10. The immunogen of claim 8, wherein e is 0; and R is hydroxyl.
11. The immunogen of claim 9, wherein Z1 is hydrogen and the Z2 crosslinker is at the para position.
12. The immunogen of claim 10, wherein Z1 is hydrogen and the Z2 crosslinker is at the para position.
13. The immunogen of claim 5 or 6, wherein a is 0; b is 0; and c is 0.
14. The immunogen of claim 13, wherein d is 0; e is 1 and R is methyl.
15. The immunogen of claim 13, wherein d is 1; e is 0; and R is hydroxyl.
16. The immunogen of claim 14, wherein Z4 is the crosslinker coupled to the antigenicity-conferring carrier material.
17. The immunogen of claim 14, wherein Z4 is the crosslinker coupled to the antigenicity-conferring carrier material.
18. The immunogen of claim 1, in which the antigenicity-conferring carrier material is selected from the group consisting of a protein, a protein fragment, a synthetic polypeptide and a semi-synthetic polypeptide.
19. The immunogen of claim 6, wherein d is 0 or 1; e is 0; and R is hydroxyl.
20. Antibodies raised against the immunogen of claim 1, wherein the antibodies are capable of binding with at least one structural epitope of a metabolite of fentanyl or of a metabolite of a fentanyl analog.
21. Antibodies raised against the immunogen of claim 18, wherein the antibodies are capable of binding with at least one structural epitope of a metabolite of fentanyl or of a metabolite of a fentanyl analog.
22. A process of preparing the antibodies as claimed in claim 20, the process comprising the steps of immunising an animal by repeated administration of the immunogen of claim 1, and collecting the resulting serum from the immunised animal.
23. A process of preparing the antibodies as claimed in claim 21, the process comprising the steps of immunising an animal by repeated administration of the immunogen of claim 18, and collecting the resulting serum from the immunised animal.
24. A conjugate of the formula:
wherein Z1 is hydrogen; Z4 is selected from the group consisting of a crosslinker covalently bonded to a labelling agent which is detectable and
wherein Z2 is a crosslinker covalently bonded to a labelling agent which is detectable at an ortho, a meta or a para position.
25. The conjugate of claim 24, wherein the crosslinker comprises:
\u2014(NH)a\u2014(CO)b\u2014Xc\u2014(CH2)d\u2014Se\u2014CO\u2014R
wherein, independently, a is 0 or 1; b is 0 or 1; X is oxygen or sulfur; c is 0 or 1; d is selected from the integers 0\u20135; e is 0 or 1 and R is selected from the group consisting of a short chain alkyl (C1-5) moiety and a hydroxyl moiety.
26. The conjugate of claim 25, wherein d is 0 or 1; e is 0; and R is hydroxyl.
27. The conjugate of claim 24, wherein the crosslinker of Z2 is at the para position.
28. The conjugate of claim 24, wherein the crosslinker terminates, at its free end, with \u2014CO\u2014R, in which R is selected from the group consisting of hydroxyl and a short chain alkyl (C1-5) moiety.
29. The conjugate of claim 28, wherein R is a short chain (C1-2) alkyl moiety.
30. The conjugate of claim 24, wherein the crosslinker comprises:
\u2014(NH)a\u2014(CO)b\u2014Xc\u2014(CH2)d\u2014Se\u2014CO\u2014R
in which, independently, a is 0 or 1; b is 0 or 1; X is oxygen or sulfur; c is 0 or 1; d is selected from the integers 1\u20135; e is 0 or 1 and R is selected from the group consisting of a short chain alkyl (C1-5) moiety and a hydroxyl moiety or a, b, c and d are 0, e is 1 and R is methyl.
31. The conjugate of claim 30 or 25, wherein R is a short chain (C1-2) alkyl moiety.
32. The conjugate of claim 30 or 25, wherein a is 1; b is 1; c is 0; and d is 2.
33. The conjugate of claim 32, wherein e is 1; and R is methyl.
34. The conjugate of claim 32, wherein e is 0; and R is hydroxyl.
35. The conjugate of claim 33, wherein Z1 is hydrogen and the Z2 crosslinker is at the para position.
36. The conjugate of claim 34, wherein Z1 is hydrogen and-the Z2 crosslinker is at the para position.
37. The conjugate of claim 30 or 25, wherein a is 0; b is 0; and c is 0.
38. The conjugate of claim 37, wherein d is 0; e is 1 and R is methyl.
39. The conjugate of claim 37, wherein d is 1; e is 0; and R is hydroxyl.
40. The conjugate of claim 38, wherein Z4 is the crosslinker covalently bonded to the labelling agent which is detectable.
41. The conjugate of claim 39, wherein Z4 is the crosslinker covalently bonded to the labelling agent which is detectable.
42. The conjugate of claim 24, wherein the detectable labelling agent is selected from the group consisting of an enzyme; a luminescent substance; and a radioactive substance; or a mixture thereof.
43. The conjugate of claim 42, in which the enzyme is a peroxidase or a mixture thereof.
44. The conjugate of claim 42, in which the luminescent substance is selected from the group consisting of a bioluminescent substance, a chemiluminescent substance and a fluorescent substance, or a mixture thereof.
45. A method for detecting, or determining the quantity of, metabolites of fentanyl, or of metabolites of fentanyl analogs in a sample, the method comprising contacting the sample with the conjugate of claim 24, or a mixture thereof and with the antibodies of claim 20 or a mixture thereof; detecting, or determining the quantity of, bound conjugate; and deducing from a calibration curve the presence, or the amount of, metabolites of fentanyl, and metabolites of fentanyl analogs in the sample.
46. The method of claim 45, wherein the antibodies are raised against an immunogen wherein Z2 is the crosslinker coupled to the antigenicity-conferring carrier material.
47. The method of claim 45, wherein Z4 of the conjugate is the crosslinker covalently bonded to the labelling agent which is detectable.
48. A kit for detecting, or determining the quantity of, metabolites of fentanyl, or metabolites of fentanyl analogs, the kit including the conjugate of claim 24 or a mixture thereof and the antibodies of claim 20 or a mixture thereof.
49. The kit of claim 48, in which the antibodies are raised against an immunogen wherein Z2 is the crosslinker coupled to the antigenicity-conferring carrier material.
50. The kit of claim 48, wherein Z4 of the conjugate is the crosslinker covalently bonded to the labelling agent which is detectable.